European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma

• Authors: ENGELHARDT Monika; UDI Josefina; KLEBER Martina; SPENCER Andrew; ROCCI Alberto; KNOP Stefan; BRUNO Benedetto; BRINGHEN Sara; PÉREZ-SIMÓN José A; ZWEEGMAN Sonja; DRIESSEN Christoph; PATRIARCA Francesca; GRAMATZKI Martin; TERPOS Evangelos; SEZER Orhan; KROPFF Martin; STRAKA Christian; JOHNSEN Hans E; WAAGE Anders; BOEGSTED Martin; LOKHORST Henk; HÁJEK Roman; MORGAN Gareth; BOCCADORO Mario; LUDWIG Heinz; CAVO Michele; POLLIACK Aaron; SONNEVELD Pieter; EINSELE Hermann; PALUMBO Antonio
• Year of publication: 2010
• Type: Article in Periodical
• Magazine / Source: Leukemia & lymphoma
• MU Faculty or unit: Faculty of Medicine
• Doi: http://dx.doi.org/10.3109/10428194.2010.516378
• Field: Oncology and hematology
• Keywords: Multiple myeloma (MM); European Myeloma Network Trialist Group (EMN-TG); novel agents; current diagnostic; therapeutic; research endeavors
• Description: Over the past two decades, not only treatment options, but also the diagnosis, staging, and risk assessment of multiple myeloma (MM), have undergone significant development, partially due to a deeper understanding of MM pathogenesis. High-dose chemotherapy with autologous stem cell transplant (SCT) still remains the standard therapy for younger patients, with novel agents now being included in both pre-transplant regimens and post-transplant consolidation/maintenance approaches. Similarly, novel agents are also being incorporated into allogeneic SCT for selected patients. In the treatment of elderly patients with MM, novel agents have been successfully incorporated into less intensive regimens, including melphalan/prednisone, low-dose dexamethasone, and cyclophosphamide/dexamethasone. While second-generation proteasome inhibitors are currently being intensively investigated, the subcutaneous administration of bortezomib, being equivalent to the established i.v. route, is now entering clinical practice.